An Open, Randomised, 2-way Crossover Study to Establish the Absolute Bioavailability of AZD9056 in Tablet Formulation (200 mg) Compared With and Intravenous Formulation (25 mg), in Healthy Volunteers
Study identifier:D1520C05285
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An Open, Randomised, 2-way Crossover Study to Establish the Absolute Bioavailability of AZD9056 in Tablet Formulation (200 mg) Compared With and Intravenous Formulation (25 mg), in Healthy Volunteers
Medical condition
Rheumatoid Arthritis
Phase
Phase 1
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Sept 2002
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
